Understanding Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute · NCT04028531
This study is collecting tissue samples and medical information from people with Chronic Lymphocytic Leukemia to see what causes the disease and find better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT04028531 on ClinicalTrials.gov |
What this trial studies
This study aims to collect tissue samples and medical information from patients with Chronic Lymphocytic Leukemia (CLL) to investigate the underlying causes and biology of the disease. By analyzing these samples, researchers hope to gain insights that could lead to the development of more effective therapies for CLL. The study includes both new and existing patients treated at the Dana-Farber Cancer Institute and focuses on various low-grade lymphoproliferative disorders.
Who should consider this trial
Good fit: Ideal candidates for this study include new and existing patients diagnosed with Chronic Lymphocytic Leukemia or related low-grade lymphoproliferative disorders.
Not a fit: Patients who do not have Chronic Lymphocytic Leukemia or related conditions may not receive any benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved therapies for patients suffering from Chronic Lymphocytic Leukemia.
How similar studies have performed: Other studies focusing on the biology of Chronic Lymphocytic Leukemia have shown promise, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New and existing patients seen for treatment of monoclonal B-cell lymphocytosis * Any low grade lymphoproliferative disorder * Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere Exclusion Criteria: \-
Where this trial is running
Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Jennifer Brown, MD,PhD — Dana-Farber Cancer Institute
- Study coordinator: Jennifer Brown, MD, PhD
- Email: Jennifer_brown@dfci.harvard.edu
- Phone: 617-582-8437
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Lymphocytic Leukemia